CryoLife Becomes Artivion as Part of Rebranding Initiative

January 18, 2022—CryoLife, Inc. announced that it was renaming and rebranding itself to Artivion, Inc., effective immediately. Effective January 24, 2022, the company will change its ticker symbol on the New York Stock Exchange to AORT from CRY. The company’s new website is https://artivion.com.

The company explained that the name is derived from the words: aorta, innovation, and vision. The new name and brand are intended to reflect the company’s evolution to focus on providing technologies for the treatment of aortic disease. 

Headquartered in suburban Atlanta, Georgia, Artivion focus includes four major groups of products: aortic stents and stent grafts, prosthetic heart valves, cryopreserved cardiac and vascular allografts, and surgical sealants.

Pat Mackin, Chairman, President, and Chief Executive Officer of Artivion, commented in the company’s press release, “Through a combination of legacy products and strategic acquisitions and divestitures over the last 5 years, we have transformed from a tissue and adhesives–focused company to one with a premier portfolio of aortic products.

“Today marks an important milestone for our company. We look forward to embarking on our next chapter as a leader in developing simple, elegant solutions to address cardiac and vascular surgeons’ most difficult clinical challenges in treating patients with aortic disease.”

Artivion will discuss its business, strategy, and rebranding at an Investor & Analyst Day on March 23, 2022, in New York, New York.